Skip to content
Screener

Merck & Co. MRK Other Non-Current Assets

Other Non-Current Assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$6.38B+7.4%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$14.27B
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.31B
Cytokinetics logo
CytokineticsCYTK
$19.41M+33.3%
Phibro Animal Health logo
Phibro Animal HealthPAHC
$100.21M-11.2%
United Therapeutics logo
United TherapeuticsUTHR
$239.5M+2.7%

Other financials

Income statement

See full
Revenue$16.6B+5.1%
Gross profit$12.2B-0.3%
Net income-$1.3B-130%
EPS (diluted)-$0.54-131%

Balance sheet

See full
Cash & equivalents$6.9B-14.6%
Total debt$56.7B+54.0%
Total equity$41.9B-14.4%
Total assets$129.80B+10.4%

Cash flow

See full
Operating cash flow$5.4B+63.1%
CapEx$893.0M+16.9%
Free cash flow$4.5B+77.0%

Valuation

See full
Market cap$317.05B+59.8%
Enterprise value$366.89B+61.5%
P/E99.9×+87.8×
P/S4.8×+1.6×

Profitability

See full
Gross margin73%-3.6pp
Net margin4.8%-21.0pp
FCF margin24.1%+1.0pp

Returns & leverage

See full
Return on equity7%-28.5pp
Debt / equity1.4×+0.6×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsFairValueDisclosure.

The source filing: Merck & Co.’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:11 PM EDT
Fiscal quarter
Q3 FY2028
Calendar quarter
Q3 2028
Accession
0000310158-26-000212
($ in millions)Fair Value Measurements Using / Level 1 / June 30, 2026Fair Value Measurements Using / Level 2 / June 30, 2026Fair Value Measurements Using / Level 3 / June 30, 2026Fair Value Measurements Using / Total / June 30, 2026Fair Value Measurements Using / Level 1 / December 31, 2025Fair Value Measurements Using / Level 2 / December 31, 2025Fair Value Measurements Using / Level 3 / December 31, 2025Fair Value Measurements Using / Total / December 31, 2025
Other assets (1)
U.S. government and agency securities100100
Publicly traded equity securities (2)5252437437
5252537537
Derivative assets (3)
Forward exchange contracts336336168168
Purchased currency options1941948484
Interest rate swap contracts31317171

Item 1. Financial Statements

FAQ

What is Merck & Co.'s other non-current assets?
Merck & Co. (MRK) reported other non-current assets of $52M in Q2 2026.
How has Merck & Co.'s other non-current assets changed year-over-year?
Merck & Co.'s other non-current assets decreased by 99.7% year-over-year, from $17.66B to $52M.
What is the long-term trend for Merck & Co.'s other non-current assets?
Over 5 years (2020 to 2025), Merck & Co.'s other non-current assets has grown at a -44.1% compound annual growth rate (CAGR), from $9.88B to $537M.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.

Ask your AI about Merck & Co.'s other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude